Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
J Cardiovasc Electrophysiol. 2011 Sep;22(9):987-93. doi: 10.1111/j.1540-8167.2011.02059.x. Epub 2011 Apr 13.
Although catheter ablation can effectively eliminate atrial fibrillation (AF), the progression of atrial remodeling increases the risk of recurrence. AF is associated with inflammation and subsequent myocardial fibrosis. We therefore examined the possibility of determining the postablation prognosis of patients with AF using biomarkers of inflammation and collagen turnover.
Subjects were 50 patients who underwent catheter ablation for drug-resistant AF. High-sensitivity CRP (hs-CRP), interleukin (IL)-6, carboxyl-terminal telopeptide of collagen type I (ICTP), metalloproteinase (MMP)-2, tissue inhibitor of MMP-2 (TIMP-2), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) were measured before and 2.2 ± 0.8 months after ablation. During the follow-up period of 14.0 (4.7-20.9) months, AF recurred in 21 of the 50 patients. Recurrence was associated with an MMP-2 elevation (860.3 ± 120.8 ng/mL vs 687.0 ± 122.5 ng/mL [in patients without recurrence]), ICTP elevation (3.2 ± 1.1 ng/mL vs 2.7 ± 0.6 ng/mL), BNP elevation, greater body mass index, nonparoxysmal AF, and hypertension (P < 0.05 for all). Serum MMP-2 and nonparoxysmal AF were shown by multivariate analysis to be independent predictors for postablation AF recurrence. Overall, hs-CRP, IL-6, ANP, and BNP levels decreased, and MMP-2, TIMP-2, and ICTP levels increased 2 months after ablation.
Our finding that markers of collagen turnover were elevated in patients who experienced AF recurrence after ablation indicate that these markers might be a useful guide to identify a subgroup of AF patients who require extensive ablation strategies. A 2-month postablation elevation in collagen turnover markers suggests that the wound healing process persists for that long after ablation.
尽管导管消融可以有效消除心房颤动(AF),但心房重构的进展增加了复发的风险。AF 与炎症和随后的心肌纤维化有关。因此,我们研究了使用炎症和胶原转化的生物标志物来确定接受导管消融的 AF 患者的消融后预后的可能性。
研究对象为 50 名接受药物难治性 AF 导管消融的患者。在消融前和消融后 2.2 ± 0.8 个月测量了高敏 C 反应蛋白(hs-CRP)、白细胞介素(IL)-6、I 型胶原羧基末端肽(ICTP)、金属蛋白酶(MMP)-2、基质金属蛋白酶抑制剂(TIMP)-2、心房利钠肽(ANP)和脑利钠肽(BNP)。在 14.0(4.7-20.9)个月的随访期间,50 名患者中有 21 名复发。复发与 MMP-2 升高(860.3 ± 120.8 ng/mL 与 687.0 ± 122.5 ng/mL[无复发患者])、ICTP 升高(3.2 ± 1.1 ng/mL 与 2.7 ± 0.6 ng/mL)、BNP 升高、更大的体重指数、非阵发性 AF 和高血压相关(所有 P < 0.05)。多变量分析显示,血清 MMP-2 和非阵发性 AF 是消融后 AF 复发的独立预测因子。总体而言,hs-CRP、IL-6、ANP 和 BNP 水平降低,MMP-2、TIMP-2 和 ICTP 水平在消融后 2 个月升高。
我们发现消融后发生 AF 复发的患者胶原转化标志物升高,这表明这些标志物可能是识别需要广泛消融策略的 AF 患者亚组的有用指标。消融后 2 个月胶原转化标志物升高表明消融后愈合过程持续了那么长时间。